NCT ID,Brief Title,Official Title,Study Type,Recruitment Status,Current Phase,Phase Details,Start Date,Completion Date,Primary Completion Date,Conditions Treated,Interventions,Intervention Types,Intervention Names,Lead Sponsor,All Sponsors,Sponsor Types,Study Locations,Countries,Cities,Enrollment,Study Population,Is Interventional,Has Drug Intervention,Has Device Intervention,Has Procedure Intervention,Has Behavioral Intervention,Has Biological Intervention,Has Radiation Intervention,Is Phase 0,Is Phase 1,Is Phase 2,Is Phase 3,Is Phase 4,Is Recruiting,Is Completed,Is Terminated,Is Suspended,Is Not Yet Recruiting,Is Active Not Recruiting
NCT00088881,"Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients With Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma,INTERVENTIONAL,TERMINATED,PHASE2,Phase 2 (Efficacy),2004-12-01T00:00:00,2011-03-01T00:00:00,2011-03-01T00:00:00,Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Testicular Lymphoma; Waldenstr√∂m Macroglobulinemia,rituximab (BIOLOGICAL); prednisone (DRUG); cyclophosphamide (DRUG); doxorubicin (DRUG); vincristine (DRUG); indium In 111 ibritumomab tiuxetan (RADIATION); radiation therapy (RADIATION); positron emission tomography (PROCEDURE),BIOLOGICAL; DRUG; DRUG; DRUG; DRUG; RADIATION; RADIATION; PROCEDURE,rituximab; prednisone; cyclophosphamide; doxorubicin; vincristine; indium In 111 ibritumomab tiuxetan; radiation therapy; positron emission tomography,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,,,,,,True,True,False,True,False,True,True,False,False,True,False,False,False,False,True,False,False,False
